ABSTRACT
TRPV4 belongs to the 'Transient Receptor Potential' (TRP) superfamily. It has been identified to profoundly affect a variety of physiological processes, including nociception, heat sensation and inflammation. Unlike other TRP superfamily channels, its role in cancers are unknown until recently when we reported TRPV4 to be required for cancer cell softness that may promote breast cancer cell extravasation and metastasis. Here, we elucidated the molecular mechanisms mediated by TRPV4 in the metastatic breast cancer cells. TRPV4-mediated signaling was demonstrated to involve Ca2+-dependent activation of AKT and downregulation of E-cadherin expression, which was abolished upon TRPV4 silencing. Functionally, TRPV4-enhanced breast caner cell transendothelial migration requires AKT activity while a combination of transcriptional and post-translational regulation contributed to the TRPV4-mediated E-cadherin downregulation. Finally, mass spectrometry analysis revealed that TRPV4 is required for the expression of a network of secreted proteins involved in extracellular matrix remodeling. In conclusion, TRPV4 may regulate breast cancer metastasis by regulating cell softness through the Ca2+-dependent AKT-E-cadherin signaling axis and regulation of the expression of extracellular proteins.
ABSTRACT
We describe a patient with clinical, radiological and pathological features of bronchiolitis obliterans organizing pneumonia. Investigation showed that this was likely to have been a delayed consequence of inhalation of nitric acid fumes (containing nitrogen dioxide) after a fire. This case shows that thorough investigation of the aetiology is important not only in clinical management but also in ensuring patients benefit from appropriate work injury compensation.
Subject(s)
Cryptogenic Organizing Pneumonia/chemically induced , Nitric Acid/poisoning , Fires , Humans , Inhalation , Male , Middle AgedABSTRACT
We describe the magnetic resonance (MR) imaging features of a rare case of fibroepithelial polyp (FEP) in a duplicated upper urinary tract. The FEP appeared as a T2-hyperintense and T1-isointense filling defect within the dilated lower moiety ureter. Post gadolinium-enhanced images revealed enhancement of the FEP without ureteral wall-thickening or enhancement. Retrograde ureterography confirmed the findings, and the patient underwent ureterotomy and removal of the polyp. Histopathological findings were consistent with an FEP. It may be possible to differentiate FEP from an ureteric carcinoma based on MR imaging features. MR imaging may be useful for preoperative diagnosis of a benign ureteric tumour, and may thus prevent an unnecessary nephroureterectomy.
Subject(s)
Magnetic Resonance Imaging/methods , Polyps/diagnosis , Polyps/pathology , Ureter/pathology , Urinary Tract/pathology , Adult , Carcinoma/diagnosis , Carcinoma/pathology , Contrast Media/pharmacology , Female , Gadolinium/pharmacology , Humans , Nephrectomy/methods , Ureteral Neoplasms/diagnosis , Ureteral Neoplasms/pathology , Urography/methods , Urologic Surgical ProceduresABSTRACT
BACKGROUND: Tumour expression of cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), erythroblastic leukaemia viral oncogene homologue-2 (ErbB2), Ki-67 and p53 in breast cancer are associated with poorer outcomes. We investigated in vivo changes of these proteins with neoadjuvant chemotherapy. PATIENTS AND METHODS: Four core biopsies were taken from 100 breast cancer patients at baseline, during and upon completion of neoadjuvant chemotherapy. Immunohistochemical expression of these proteins were evaluated and correlated with clinicopathological features, clinical response and progression-free survival (PFS). RESULTS: There was a statistically significant change from positivity to negativity in COX-2 expression with chemotherapy (P = 0.002), predominantly in clinical responders (P = 0.002). COX-2-positive tumours that remained positive had shorter PFS than those that turned negative. Estrogen receptor (ER)+ and COX-2+ tumours at baseline that remained COX-2+ fared worse than those that became COX-2 negative (PFS 27 versus 52 months, P = 0.002). No significant changes in IHC expression were observed for ER, progesterone receptor, ErbB2, EGFR, p53 or Ki67. CONCLUSIONS: Chemotherapy induced change in COX-2 expression from positivity to negativity predominantly among clinical responders and is associated with longer PFS. Interaction between COX-2 and ER was observed, suggesting that some hormone receptor-positive patients may benefit from combining COX-2 inhibition with hormonal therapy.
Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Breast Neoplasms/therapy , Neoadjuvant Therapy , Adult , Aged , Breast Neoplasms/pathology , Cyclooxygenase 2/metabolism , Disease-Free Survival , ErbB Receptors/metabolism , Female , Humans , Immunohistochemistry , Ki-67 Antigen/metabolism , Middle Aged , Neoplasm Staging , Receptor, ErbB-2/metabolism , Tumor Suppressor Protein p53/metabolismABSTRACT
We report a rare case of renal cell carcinoma with metastasis to the patella in a 49-year-old man, who presented with seven months of left knee pain after a fall. Only two similar cases have been reported. Patellar metastasis is rare because it has a relatively poor blood supply and microemboli would have been sieved out by the pulmonary circulation. Patellectomy is the usual treatment for such cases. We suspect that the preferential metastasis in our patient is a result of tropism. Our treatment for this patient is unique. We opted for a patella-preserving operation involving the use of cryotherapy, as this treatment modality preserved the quality of life. An opportunistic biopsy one year later confirmed the absence of active disease within the patella. This case uniquely provides human in vivo histological confirmation that an intralesional procedure with local and systemic adjuvant therapy effectively controls local disease.
Subject(s)
Bone Neoplasms/secondary , Bone Neoplasms/therapy , Carcinoma, Renal Cell/secondary , Kidney Neoplasms/pathology , Patella/pathology , Bone Neoplasms/diagnosis , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Cryotherapy/methods , Follow-Up Studies , Humans , Kidney Neoplasms/surgery , Male , Middle Aged , Risk Assessment , Treatment OutcomeABSTRACT
Myelolipoma within an adrenal cortical adenoma is a very rare cause of adrenal incidentaloma, and only nine cases have been reported in the English and Japanese literature. We report a 66-year-old Chinese man, with a history of hypertension and hyperlipidaemia, who presented with lower limb oedema and had a computed tomography (CT ) of the abdomen done to exclude intra-abdominal mass. His lower limb symptoms resolved after switching his antihypertensive medication. CT of the abdomen showed a large heterogeneously-enhancing mass in the left suprarenal region, measuring 72 mm by 55 mm. Clinical history, physical examination and laboratory results did not show any evidence to suggest metabolic disorder such as Cushing's syndrome, hyperaldosteronism or catecholamine hypersecretion. The patient underwent a left adrenalectomy, and a histopathological study confirmed the mass to be a non-functional adrenal cortical adenoma containing myelolipoma. The patient was well postoperatively and was discharged uneventfully. To the best of our knowledge, this is the first non-functional adrenal cortical adenoma reported; in the nine cases of myelolipoma within an adrenal cortical adenoma reported previously, all the patients had Cushing's syndrome. The literature on synchronous myelolipoma with adrenal adenoma, and myelolipoma within functional adrenal adenoma, is reviewed.
Subject(s)
Adrenal Cortex Neoplasms/pathology , Adrenocortical Adenoma/pathology , Myelolipoma/pathology , Adrenal Cortex Neoplasms/complications , Adrenal Cortex Neoplasms/surgery , Adrenalectomy , Adrenocortical Adenoma/complications , Adrenocortical Adenoma/surgery , Aged , Humans , Incidental Findings , Male , Myelolipoma/complications , Myelolipoma/surgeryABSTRACT
Tumor suppressor genes (TSGs) often locate at chromosomal regions with frequent deletions in tumors. Loss of 16q23 occurs frequently in multiple tumors, indicating the presence of critical TSGs at this locus, such as the well-studied WWOX. Herein, we found that ADAMTS18, located next to WWOX, was significantly downregulated in multiple carcinoma cell lines. No deletion of ADAMTS18 was detected with multiplex differential DNA-PCR or high-resolution 1-Mb array-based comparative genomic hybridization (CGH) analysis. Instead, methylation of the ADAMTS18 promoter CpG Island was frequently detected with methylation-specific PCR and bisulfite genome sequencing in multiple carcinoma cell lines and primary carcinomas, but not in any nontumor cell line and normal epithelial tissue. Both pharmacological and genetic demethylation dramatically induced the ADAMTS18 expression, indicating that CpG methylation directly contributes to the tumor-specific silencing of ADAMTS18. Ectopic ADAMTS18 expression led to significant inhibition of both anchorage-dependent and -independent growth of carcinoma cells lacking the expression. Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.
Subject(s)
ADAM Proteins/genetics , Chromosomes, Human, Pair 16 , Esophageal Neoplasms/genetics , Genes, Tumor Suppressor , Nasopharyngeal Neoplasms/genetics , ADAMTS Proteins , Cell Growth Processes/genetics , Cell Line, Tumor , DNA Methylation , Down-Regulation , Female , Gene Deletion , Gene Expression Regulation, Neoplastic , Gene Silencing , HeLa Cells , Humans , Male , Nucleic Acid Hybridization , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Diabetic fibrous mastopathy is reported in a 37-year-old premenopausal woman. A known case of insulin-dependent diabetes mellitus, she presented with bilateral hard breast lumps, which were suggestive of malignancy on both ultrasonography and mammography. Fine-needle aspiration cytology and core biopsy showed fibrosis. An incisional biopsy further excluded malignancy and was conclusive for diabetic fibrous mastopathy.
Subject(s)
Diabetes Complications/pathology , Fibrocystic Breast Disease/pathology , Adult , Biopsy, Fine-Needle , Female , Fibrocystic Breast Disease/diagnostic imaging , Histocytochemistry , Humans , Mammography , Premenopause , UltrasonographyABSTRACT
Large genomic rearrangements have been reported to account for about 10-15% of BRCA1 gene mutations. Approximately, 90 BRCA rearrangements have been described to date, all of which but one have been reported in Caucasian populations of predominantly Western European descent. Knowledge of BRCA genomic rearrangements in Asian populations is still largely unknown. In this study, we have investigated for the presence of BRCA rearrangements among Asian patients with early onset or familial history of breast or ovarian cancer. Using multiplex ligation-dependent probe amplification (MLPA), we have analyzed 100 Singapore patients who previously tested negative for deleterious BRCA mutations by the conventional polymerase chain reaction-based mutation detection methods. Three novel BRCA rearrangements were detected, two of which were characterized. The patients with the rearrangements, a BRCA1 exon 13 duplication, a BRCA1 exon 13-15 deletion and a BRCA2 exon 4-11 duplication, comprise 3% of those previously tested negative for BRCA mutations. Of the BRCA1 and BRCA2 pathogenic mutations identified in our studies on Asian high-risk breast and ovarian patients with cancer to date, these rearrangements constitute 2/19 and 1/2 of the BRCA1 and BRCA2 pathogenic mutations, respectively. Given the increasing number of rearrangements reported in recent years and their contribution to the BRCA mutation spectrum, the presence of BRCA large exon rearrangements in Asian populations should be investigated where clinical, diagnostic service is recommended.
Subject(s)
Breast Neoplasms/genetics , Gene Rearrangement , Genes, BRCA1 , Genes, BRCA2 , Ovarian Neoplasms/genetics , Adolescent , Adult , Asian People/genetics , Base Sequence , DNA Primers/genetics , DNA, Neoplasm/genetics , Exons , Female , Humans , Middle Aged , Molecular Sequence Data , Mutation , Nucleic Acid Amplification Techniques , Sequence Deletion , SingaporeSubject(s)
Breast Neoplasms/ethnology , Breast Neoplasms/genetics , Genes, BRCA1 , Haplotypes , Ovarian Neoplasms/ethnology , Ovarian Neoplasms/genetics , Age of Onset , BRCA1 Protein/metabolism , Ethnicity , Female , Founder Effect , Humans , Microsatellite Repeats , Middle Aged , Mutation , SingaporeABSTRACT
BACKGROUND: Celecoxib is a selective cyclooxygenase-2 inhibitor with antitumor and antiangiogenic activity. We sought to determine pharmacodynamic change in tumors of patients with nasopharyngeal carcinoma (NPC) treated with celecoxib. METHODS: Tumor biopsies were obtained before and after treatment with celecoxib 400 mg b.i.d. for 14 days in patients with newly diagnosed, untreated NPC. Tumor angiogenesis and cell proliferation were assessed by immunohistochemistry and gene expression by microarray analysis. Plasma celecoxib concentrations were obtained on days 8 and 14. RESULTS: Paired samples were analyzed in 15 patients. Microvessel density was reduced in post-treatment samples and mean celecoxib levels reached therapeutic levels. Thirty-five genes (27 down-regulated, eight up-regulated) were differentially expressed on microarray analysis (p < 0.001). Down-regulated genes included cell cycle regulation-related (cyclin-dependent kinase 2, YES1), transcription factor (TRIP-Br2), whereas the antigen processing and presentation-related gene HLA-DM B was up-regulated. CONCLUSION: Celecoxib reduced angiogenesis and induced tumor transcriptional changes. Further characterization of these transcriptional changes in vivo is needed to provide further insights into the effects of celecoxib in neoplastic tissue. Our findings provide a rationale for clinical studies aimed at assessing the efficacy of celecoxib in the treatment of NPC.
Subject(s)
Antineoplastic Agents/pharmacology , Blood Vessels/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Nasopharyngeal Neoplasms/drug therapy , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Adult , Aged , Antineoplastic Agents/blood , Antineoplastic Agents/therapeutic use , Celecoxib , Cyclooxygenase 2/metabolism , Female , Genes, Neoplasm , Humans , Immunohistochemistry , Ki-67 Antigen/metabolism , Male , Middle Aged , Nasopharyngeal Neoplasms/genetics , Pyrazoles/blood , Pyrazoles/therapeutic use , Sulfonamides/blood , Sulfonamides/therapeutic use , Transcription, Genetic/drug effectsABSTRACT
BACKGROUND: Mammary metaplastic carcinoma encompasses epithelial-only carcinoma (high-grade adenosquamous carcinoma or pure squamous cell carcinoma), biphasic epithelial and sarcomatoid carcinoma and monophasic spindle cell carcinoma. AIM: To evaluate the clinicopathological features of a large series of 34 metaplastic carcinomas. METHODS: 10 epithelial-only, 14 biphasic and 10 monophasic metaplastic carcinomas were assessed for nuclear grade, hormone receptor status, HER2/neu (cerbB2) oncogene expression, Ki-67 and p53, lymph node status and recurrence on follow-up. RESULTS: Intermediate to high nuclear grade were assessed in most (33/34) tumours. Oestrogen and progesterone receptors were negative in 8 of 10 epithelial-only, all 14 biphasic, and 9 of 10 monophasic tumours, cerbB2 was negative in 7 of 10 epithelial-only, all 14 biphasic and 8 of 10 monophasic tumours. Ki-67 was found to be positive in 6 of 10 epithelial-only, 6 of 14 biphasic, and 7 of 10 monophasic tumours, whereas p53 was positive in 6 of 10 epithelial-only, 7 of 14 biphasic, and 8 of 10 monophasic tumours. Lymph node metastases were seen in 7 of 7 epithelial-only, 7 of 11 biphasic, and 3 of 7 monophasic tumours. Recurrences were seen in 4 of 7 epithelial-only, 8 of 9 biphasic, and 4 of 9 monophasic tumours. CONCLUSIONS: All three subtypes of metaplastic carcinoma are known to behave aggressively, and should be differentiated from the low-grade fibromatosis-like metaplastic carcinoma, which does not metastasize. Oncological treatment options may be limited by the frequently negative status of hormonal receptor and cerbB2.
Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Neoplasm Proteins/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenocarcinoma/secondary , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Carcinoma/metabolism , Carcinoma/pathology , Carcinoma/secondary , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/secondary , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Metaplasia , Middle Aged , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Sarcoma/metabolism , Sarcoma/pathology , Sarcoma/secondarySubject(s)
Breast Neoplasms/pathology , Carcinoma, Lobular/pathology , Lymph Nodes/pathology , Sentinel Lymph Node Biopsy/standards , Axilla , Breast Neoplasms/metabolism , Breast Neoplasms/surgery , Carcinoma, Lobular/metabolism , Carcinoma, Lobular/surgery , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Keratins/analysis , Lymph Nodes/chemistry , Lymphatic Metastasis/diagnosis , Mastectomy/methods , Middle Aged , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature. One thousand nine hundred and forty-four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers. In addition, haematoxylin and eosin-stained sections of these tumours were studied for several morphological parameters. The findings were correlated with patient and tumour characteristics and outcome data. Tumours were classified into two groups: (1) tumours with basal phenotype [expressing one or both basal markers (CK5/6 and/or CK14)] and (2) tumours with myoepithelial phenotype (expressing SMA and/or p63). Group 1 was further subdivided into two subgroups: (A) dominant basal pattern (more than 50% of cells positive) and (B) basal characteristics (10-50% of cells positive). Group 1 tumours constituted 18.6% (8.6% and 10% for groups 1A and 1B, respectively) and group 2 constituted 13.7% of the cases. In both groups, the most common histological types were ductal/no specific type, tubular mixed and medullary-like carcinomas; the majority of these tumours were grade 3. There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis. In addition, associations were found with loss of expression of steroid hormone receptors and FHIT proteins and positive expression of p53 and EGFR. The most common characteristics in group 1 were larger size, high-grade comedo-type necrosis, development of tumour recurrence, and absence of lymph node disease. Group 2 tumours were more common in younger patients and were associated with central acellular zones, basaloid change, and positive E-cadherin protein expression. Group 1 characteristics were associated with both reduced overall survival (OS) [log rank (LR) = 22.5, p < 0.001] and reduced disease-free interval (DFI) (LR = 30.1, p < 0.001), while group 2 characteristics showed an association with OS (LR = 5, p = 0.02) but not with DFI. Multivariate analysis showed that basal, but not myoepithelial, phenotype has an independent value in predicting outcome. Breast cancers with basal and myoepithelial phenotypes are distinct groups of tumours that share some common morphological features and an association with poor prognosis. The basal rather than the myoepithelial phenotype has the strongest relationship with patient outcome.
Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Myoepithelioma/pathology , Neoplasms, Basal Cell/pathology , Actins/genetics , Adult , Age Factors , Aged , Biomarkers, Tumor/analysis , Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Cadherins/analysis , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/mortality , Cell Differentiation , Disease-Free Survival , ErbB Receptors/analysis , Female , Genes, p53 , Humans , Immunohistochemistry , Keratins/genetics , Middle Aged , Multivariate Analysis , Myoepithelioma/metabolism , Myoepithelioma/mortality , Necrosis , Neoplasms, Basal Cell/immunology , Neoplasms, Basal Cell/mortality , Receptors, Androgen/analysis , Staining and Labeling , Survival RateABSTRACT
Protocadherins constitute the largest subgroup in the cadherin superfamily of cell adhesion molecules. Their major functions are poorly understood, although some are implicated in nervous system development. As tumor-specific promoter methylation is a marker for tumor suppressor genes (TSG), we searched for epigenetically inactivated TSGs using methylation-subtraction combined with pharmacologic demethylation, and identified the PCDH10 CpG island as a methylated sequence in nasopharyngeal carcinoma (NPC). PCDH10 is broadly expressed in all normal adult and fetal tissues including the epithelia, though at different levels. It resides at 4q28.3--a region with hemizygous deletion detected by array-CGH in NPC cell lines; however, PCDH10 itself is not located within the deletion. In contrast, its transcriptional silencing and promoter methylation were frequently detected in multiple carcinoma cell lines in a biallelic way, including 12/12 nasopharyngeal, 13/16 esophageal, 3/4 breast, 5/5 colorectal, 3/4 cervical, 2/5 lung and 2/8 hepatocellular carcinoma cell lines, but not in any immortalized normal epithelial cell line. Aberrant methylation was further frequently detected in multiple primary carcinomas (82% in NPC, 42-51% for other carcinomas), but not normal tissues. The transcriptional silencing of PCDH10 could be reversed by pharmacologic demethylation with 5-aza-2'-deoxycytidine or genetic demethylation with double knockout of DNMT1 and DNMT3B, indicating a direct epigenetic mechanism. Ectopic expression of PCDH10 strongly suppressed tumor cell growth, migration, invasion and colony formation. Although the epigenetic and genetic disruptions of several classical cadherins as TSGs have been well documented in tumors, this is the first report that a widely expressed protocadherin can also function as a TSG that is frequently inactivated epigenetically in multiple carcinomas.
Subject(s)
Cadherins/genetics , Carcinoma/genetics , Epigenesis, Genetic , Esophageal Neoplasms/genetics , Genes, Tumor Suppressor , Nasopharyngeal Neoplasms/genetics , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Cell Movement/genetics , DNA (Cytosine-5-)-Methyltransferase 1 , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , DNA Methylation/drug effects , Decitabine , Gene Silencing/drug effects , Humans , Promoter Regions, Genetic , Protocadherins , Sequence Deletion , Transcription, Genetic/genetics , DNA Methyltransferase 3BABSTRACT
Considerable progress has been made in understanding breast lesions utilizing molecular methods, but conventional morphology, simple immunohistochemical stains and common sense still prevail in diagnosing the vast majority of breast disease. The focus of this review is to identify the most common breast lesions sent to our consultation practice, and to reiterate salient diagnostic features, differential diagnoses and common pitfalls in identifying these lesions. Separation of epithelial proliferative lesions and differentiation between usual epithelial hyperplasia (UEH) and atypical ductal hyperplasia (ADH) are the most common problems encountered in our Consultation practice. Differentiation between UEH and ADH is based on the assumption that ADH is a clonal process, recognized by a uniform phenotype and more recently described immunohistochemical markers such as differential cytokeratin and also hormone receptor expression. Difficulty in subtyping invasive carcinomas and exclusion of in situ and/or invasive carcinoma in a sclerosing lesion is also commonly noted. Finally, problems in distinguishing various papillary and fibroepithelial lesions are also encountered. The use of common immunohistochemical stains such as various cytokeratin and myoepithelial markers, E-cadherin and hormone receptors is helpful in solving most of these diagnostic dilemmas.
Subject(s)
Breast Diseases/diagnosis , Mammary Glands, Human/pathology , Referral and Consultation , Adult , Breast Diseases/pathology , Breast Neoplasms/diagnosis , Breast Neoplasms/pathology , Carcinoma in Situ/diagnosis , Carcinoma in Situ/pathology , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/pathology , Carcinoma, Intraductal, Noninfiltrating/diagnosis , Carcinoma, Intraductal, Noninfiltrating/pathology , Carcinoma, Papillary/diagnosis , Carcinoma, Papillary/pathology , Diagnosis, Differential , Female , Fibrosis/diagnosis , Fibrosis/pathology , Humans , Hyperplasia/diagnosis , Hyperplasia/pathology , Middle Aged , Neoplasms, Fibroepithelial/diagnosis , Neoplasms, Fibroepithelial/pathology , Papilloma/diagnosis , Papilloma/pathologyABSTRACT
OBJECTIVES: To determine whether cyclooxygenase-2 (COX-2) is overexpressed in Warthin's tumours, and to characterize its pattern of expression. METHODS: Twenty-one paraffin-embedded Warthin's tumour specimens were analysed by immunohistochemical staining for expression of human COX-2. Semi-quantitative analysis of the staining was performed. RESULTS: In all of the specimens, we found that there was overexpression of COX-2 within the epithelial component of the tumours, with no expression in the lymphoid components. There was also overexpression of COX-2 in the salivary duct system of normal parotid tissue. CONCLUSIONS: Our results suggest that COX-2 is up-regulated in the epithelial component of Warthin's tumours. Our findings support the hypothesis that Warthin's tumours originate from heterotopic ductal epithelial cells of the parotid gland. The role of COX-2 expression in the pathogenesis of Warthin's tumours remains to be determined.
Subject(s)
Adenolymphoma/enzymology , Cyclooxygenase 2/analysis , Adult , Aged , Aged, 80 and over , Epithelium/enzymology , Humans , Immunohistochemistry/methods , Lymphoid Tissue/enzymology , Male , Middle Aged , Parotid Gland/enzymology , Salivary Ducts/enzymologyABSTRACT
Tuberculosis (TB) of the liver is usually associated with miliary spread. Macronodular TB of the liver is rare. A case of macronodular TB of the liver in a 31-year-old woman causing portal vein thrombosis and portal hypertension is presented. Ultrasound and CT appearances are described. There was coexistent ileo-caecal TB with extensive mesenteric and retroperitoneal lymphadenopathy. Macronodular TB should be considered in the differential diagnosis when a patient presents with multiple calcified masses in the liver with portal vein thrombosis and portal hypertension.
Subject(s)
Hypertension, Portal/etiology , Portal Vein , Tuberculosis, Hepatic/complications , Venous Thrombosis/etiology , Adult , Female , Humans , Hypertension, Portal/diagnostic imaging , Tomography, X-Ray Computed , Tuberculosis, Hepatic/diagnostic imaging , Ultrasonography , Venous Thrombosis/diagnostic imagingABSTRACT
BACKGROUND: Nitric oxide synthase (NOS), particularly endothelial and inducible forms (e/i-NOS), are expressed in various cancers, including breast cancer. In mammary fibroepithelial lesions, NOS expression in stromal cells has been reported to be lower in fibroadenomas than in phyllodes tumours. AIMS: To investigate NOS expression in phyllodes tumours of varying degrees of malignancy. METHODS: One hundred and sixty seven mammary phyllodes tumours (97 benign, 47 borderline malignant, and 23 frankly malignant) were evaluated for e-NOS and i-NOS expression by immunohistochemistry. Correlations with previously reported expression of stromal vascular growth factor (VEGF) and microvessel density were also performed. RESULTS: Stromal expression of e-NOS was absent, weak, moderate, and strong in 43%, 31%, 13%, and 13% of benign tumours; 17%, 26%, 13%, and 44% of borderline malignant tumours; and 17%, 35%, 13%, and 35% of frankly malignant tumours, respectively. Stromal expression of i-NOS was 77%, 18%, 4%, and 1% in benign tumours; 42%, 28%, 19%, and 11% in borderline malignant tumours; and 43%, 13%, 26%, and 18% in frankly malignant tumours, respectively. Stromal expression of both i-NOS and e-NOS was significantly different between the benign and malignant (borderline and frank) groups of phyllodes tumours (p < 0.0001). Furthermore, the expression of i-NOS correlated with stromal VEGF expression and microvessel density. The expression of NOS in the epithelial cells was strong, and showed no differences between the different groups of tumours. CONCLUSIONS: Higher stromal expression of NOS in phyllodes tumours is associated with malignancy, suggesting a possible role in malignant progression, particularly metastasising potential.